CDC NEWS


powered by Surfing Waves


Latest News


The Most Common COVID-19 Booster Shot Questions, Answered


23 Sep 2021

The Food and Drug Administration has authorized Pfizer COVID-19 booster shots for people over the age of 65 and other at-risk Americans. The agency’s decision was the latest twist in the ongoing debate about when coronavirus booster shots would be necessary — and for whom.


Covid Live Updates: Extra Dose of J. & J. Vaccine Raises Protection, Company Says


21 Sep 2021

In a clinical trial, researchers found that two doses of the vaccine delivered 94 percent efficacy against mild to severe Covid-19.


Breakthrough Infections in Vaccinated People Less Likely to Cause ‘Long COVID’


14 Sep 2021

There’s no question that vaccines are making a tremendous difference in protecting individuals and whole communities against infection and severe illness from SARS-CoV-2, the coronavirus that causes COVID-19. And now, there’s yet another reason to get the vaccine: in the event of a breakthrough infection, people who are fully vaccinated also are substantially less likely to develop Long COVID Syndrome, which causes brain fog, muscle pain, fatigue, and a constellation of other debilitating symptoms that can last for months after recovery from an initial infection.


COVID-19 Infected Many More Americans in 2020 than Official Tallies Show


07 Sep 2021

At the end of last year, you may recall hearing news reports that the number of COVID-19 cases in the United States had topped 20 million. While that number came as truly sobering news, it also likely was an underestimate. Many cases went undetected due to limited testing early in the year and a large number of infections that produced mild or no symptoms. Now, a recent article published in Nature offers a more-comprehensive estimate that puts the true number of infections by the end of 2020 at more than 100 million [1]. That’s equal to just under a third of the U.S. population of 328 million. This revised number shows just how rapidly this novel coronavirus spread through the country last year. It also brings home just how timely the vaccines have been—and continue to be in 2021—to protect our nation’s health in this time of the pandemic.


Vaccines prevented up to 140,000 COVID-19 deaths in U.S.


24 Aug 2021

Three highly effective COVID-19 vaccines are available in the U.S. These vaccines have been shown to slow the spread of the virus and reduce COVID-19 deaths. About half of the population has been fully vaccinated as of August 2021. But vaccination rates have varied across the country, with some states proceeding much faster than others.




Articles


Association of Race/Ethnicity With Likeliness of COVID-19 Vaccine Uptake Among Health Workers and the General Population in the San Francisco Bay Area


30 Mar 2021

Surveys have demonstrated racial differences in the public’s willingness to receive a COVID-19 vaccine1,2 but have not directly compared vaccine intentions among health workers and the general public.3 We investigated COVID-19 vaccine intentions among racially and ethnically diverse samples of health workers and the general population.




SARS-CoV-2 infection of the oral cavity and saliva


25 Mar 2021

Despite signs of infection—including taste loss, dry mouth and mucosal lesions such as ulcerations, enanthema and macules—the involvement of the oral cavity in coronavirus disease 2019 (COVID-19) is poorly understood. To address this, we generated and analyzed two single-cell RNA sequencing datasets of the human minor salivary glands and gingiva (9 samples, 13,824 cells), identifying 50 cell clusters. Using integrated cell normalization and annotation, we classified 34 unique cell subpopulations between glands and gingiva. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral entry factors such as ACE2 and TMPRSS members were broadly enriched in epithelial cells of the glands and oral mucosae. Using orthogonal RNA and protein expression assessments, we confirmed SARS-CoV-2 infection in the glands and mucosae. Saliva from SARS-CoV-2-infected individuals harbored epithelial cells exhibiting ACE2 and TMPRSS expression and sustained SARS-CoV-2 infection. Acellular and cellular salivary fractions from asymptomatic individuals were found to transmit SARS-CoV-2 ex vivo. Matched nasopharyngeal and saliva samples displayed distinct viral shedding dynamics, and salivary viral burden correlated with COVID-19 symptoms, including taste loss. Upon recovery, this asymptomatic cohort exhibited sustained salivary IgG antibodies against SARS-CoV-2. Collectively, these data show that the oral cavity is an important site for SARS-CoV-2 infection and implicate saliva as a potential route of SARS-CoV-2 transmission.




Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study


17 Mar 2021

The vast majority of people who recover from Covid-19 remain protective immunity from the virus for at least six months, researchers reported on Wednesday in a large study from Denmark. The study revealed protective immunity to be approximately 80–83% in people younger than 65 years. We found no difference in immunity over the study period. Among those aged 65 years and older, immunity was estimated to be approximately 47%.




SARS-CoV-2 Vaccines


26 Feb 2021

Shortly after SARS-CoV emerged at the turn of the 21st century, the spike (S) protein (particularly in its prefusion [native] conformation) was identified as the immunodominant antigen of the virus. Evaluation of patients with SARS-CoV-2 revealed that binding and neutralizing antibodies primarily target the receptor-binding domain of the S1 subunit.




SARS-CoV-2 Variants of Concern in the United States—Challenges and Opportunities


17 Feb 2021

. SARS-CoV-2, like other RNA viruses, constantly changes through mutation, with new variants occurring over time. Generally, when new variants become more common, they do so because of some selective advantage to the virus.




Enroll for Free